{"id":"ezogabine-retigabine","safety":{"commonSideEffects":[{"rate":"25–30%","effect":"Dizziness"},{"rate":"20–25%","effect":"Somnolence"},{"rate":"15–20%","effect":"Confusion"},{"rate":"10–15%","effect":"Vertigo"},{"rate":"10–15%","effect":"Tremor"},{"rate":"10–15%","effect":"Diplopia"},{"rate":"5–10%","effect":"Urinary retention"},{"rate":"5–10%","effect":"Blue discoloration of skin/sclera"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ezogabine is a potassium channel opener that stabilizes the open state of KCNQ (Kv7) voltage-gated potassium channels. By enhancing potassium channel activity, it hyperpolarizes neuronal membranes and reduces the likelihood of action potential firing, thereby decreasing seizure activity. This mechanism is distinct from other anticonvulsants and provides an alternative approach to seizure control.","oneSentence":"Ezogabine opens voltage-gated potassium channels in neurons, increasing potassium efflux and reducing neuronal excitability to suppress seizures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:44.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT06941168","phase":"","title":"Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer: A Multicenter Propensity Score Matching Analysis","status":"COMPLETED","sponsor":"Fujian Medical University","startDate":"2015-01","conditions":"Advanced Gastric Cancer","enrollment":1099},{"nctId":"NCT04912856","phase":"PHASE3","title":"An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE","status":"TERMINATED","sponsor":"Xenon Pharmaceuticals Inc.","startDate":"2021-08-17","conditions":"Epilepsy, Epilepsy in Children, Epilepsy; Seizure","enrollment":8},{"nctId":"NCT04639310","phase":"PHASE3","title":"XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy","status":"TERMINATED","sponsor":"Xenon Pharmaceuticals Inc.","startDate":"2021-03-29","conditions":"Epilepsy, Epilepsy in Children, Epilepsy; Seizure","enrollment":8},{"nctId":"NCT01721317","phase":"PHASE4","title":"Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-12-19","conditions":"Seizures","enrollment":6},{"nctId":"NCT01607346","phase":"PHASE4","title":"An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2013-03-27","conditions":"Epilepsy","enrollment":10},{"nctId":"NCT01494584","phase":"PHASE2","title":"Study in Pediatric Subjects With Epilepsy","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-07-25","conditions":"Epilepsy","enrollment":5},{"nctId":"NCT01668654","phase":"PHASE3","title":"Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-09-04","conditions":"Epilepsy","enrollment":4},{"nctId":"NCT03043560","phase":"PHASE2","title":"Study to Treat Major Depressive Disorder With a New Medication","status":"COMPLETED","sponsor":"James Murrough","startDate":"2017-09-25","conditions":"Depressive Disorder, Anhedonia","enrollment":45},{"nctId":"NCT00310375","phase":"PHASE3","title":"Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Epilepsy","enrollment":181},{"nctId":"NCT01336621","phase":"PHASE3","title":"Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-21","conditions":"Epilepsy","enrollment":98},{"nctId":"NCT01777139","phase":"PHASE3","title":"A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-11","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT02450552","phase":"PHASE2","title":"Clinical Trial of Ezogabine (Retigabine) in ALS Subjects","status":"COMPLETED","sponsor":"Brian Wainger","startDate":"2015-06","conditions":"Amyotrophic Lateral Sclerosis","enrollment":65},{"nctId":"NCT02149836","phase":"PHASE2","title":"Study to Treat Major Depressive Disorder (MDD) With a New Medication","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-08","conditions":"Major Depressive Disorder, Depression","enrollment":18},{"nctId":"NCT00310388","phase":"PHASE3","title":"Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2006-07-05","conditions":"Epilepsy","enrollment":376},{"nctId":"NCT01691872","phase":"PHASE1","title":"Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Epilepsy, Partial","enrollment":""},{"nctId":"NCT01648101","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-08-29","conditions":"Epilepsy","enrollment":76},{"nctId":"NCT01332513","phase":"PHASE1","title":"An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-10","conditions":"Epilepsy","enrollment":36},{"nctId":"NCT01480609","phase":"PHASE1","title":"Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-30","conditions":"Epilepsy","enrollment":8},{"nctId":"NCT01583036","phase":"PHASE1","title":"An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-16","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT01462669","phase":"PHASE1","title":"Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-10","conditions":"Epilepsy","enrollment":1},{"nctId":"NCT00612105","phase":"PHASE2","title":"Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-10","conditions":"Postherpetic Neuralgia","enrollment":187},{"nctId":"NCT02727101","phase":"PHASE4","title":"Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.","status":"TERMINATED","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","startDate":"2015-11","conditions":"Epilepsy","enrollment":8},{"nctId":"NCT00235755","phase":"PHASE3","title":"Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12","conditions":"Seizures","enrollment":539},{"nctId":"NCT00232596","phase":"PHASE3","title":"Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Seizures","enrollment":306},{"nctId":"NCT01462656","phase":"","title":"Risk of Urinary Retention With Retigabine","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-02","conditions":"Epilepsy","enrollment":1},{"nctId":"NCT01721213","phase":"","title":"Trobalt™ Products Risk Survey","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09","conditions":"Epilepsy","enrollment":1},{"nctId":"NCT01823159","phase":"PHASE3","title":"Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study","status":"COMPLETED","sponsor":"University Hospital of Mont-Godinne","startDate":"2013-04","conditions":"Epilepsy","enrollment":15},{"nctId":"NCT01227902","phase":"PHASE3","title":"Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07","conditions":"Epilepsy","enrollment":203},{"nctId":"NCT01938560","phase":"","title":"REMS Retigabine Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Epilepsy","enrollment":1},{"nctId":"NCT01587339","phase":"","title":"Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Epilepsy","enrollment":6498},{"nctId":"NCT01457989","phase":"","title":"Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-08","conditions":"Epilepsy, Partial","enrollment":1},{"nctId":"NCT01214278","phase":"PHASE4","title":"Bioavailability of Different n-3 Fatty Acid Formulations","status":"COMPLETED","sponsor":"Gottfried Wilhelm Leibniz Universität Hannover","startDate":"2010-10","conditions":"Health","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"COMPLEX PARTIAL SEIZURES"}],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ezogabine/retigabine","genericName":"ezogabine/retigabine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ezogabine opens voltage-gated potassium channels in neurons, increasing potassium efflux and reducing neuronal excitability to suppress seizures. Used for Partial-onset seizures (adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}